Annita Tanini

interim principal financial officer and principal accounting officer, Keros Therapeutics, Inc.

In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.

Annita Tanini has been interim principal financial officer and principal accounting officer of Keros Therapeutics, Inc. since August 4, 2026, according to the company's filing of July 22, 2026.¹

The filing gives Annita Tanini's previous role as Corporate Controller and Vice President, Finance at Keros Therapeutics, Inc.¹ Annita Tanini already worked at Keros Therapeutics, Inc. when appointed, so the record counts the move as an internal promotion.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Keros Therapeutics, Inc. (KROS) Pharmaceutical Preparations	interim principal financial officer and principal accounting officer	In the seat, on an interim basis	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

August 4, 2026effective
Keros Therapeutics, Inc. named Annita Tanini interim principal financial officer and principal accounting officer, effective August 4, 2026. Profile of Keith Regnante.
[1] Filing by Keros Therapeutics, Inc., filed with the SEC on July 22, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Keros Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 22, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Annita Tanini wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.